Transition Therapeutics Inc  

(Public, TSE:TTH)   Watch this stock  
Find more results for TTH
-0.03 (-0.38%)
Delayed:   1:12PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 7.67 - 7.85
52 week 4.04 - 9.25
Open 7.67
Vol / Avg. 338.00/2,273.00
Mkt cap 251.24M
P/E     -
Div/yield     -
EPS -0.37
Shares 32.00M
Beta 0.32
Inst. own     -
Sep 18, 2014
Q4 2014 TRANSITION THERAPEUTICS INC Earnings Release (Estimated)
Sep 9, 2014
Transition Therapeutics Inc at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - 0.13%
Operating margin - -5.76%
EBITD margin - 40.89%
Return on average assets -37.89% 0.06%
Return on average equity -42.94% 0.07%
Employees 15 -
CDP Score - -


+1-416-2607770 (Phone)
+1-416-2602886 (Fax)

Website links


Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with large markets. The Company�s s technologies in development are ELND005 (AZD-103) for the treatment of Alzheimer�s disease and bipolar disorder; TT-401/402 for the treatment of diabetes ,and TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, neuropathic pain, Alzheimer�s disease, traumatic brain injury and intracerebral haemorrhage. The Company has one wholly owned material subsidiary, Waratah Pharmaceuticals Inc. (Waratah), which is engaged in the development and commercialization of its ELND005 (AZD-103); the type II diabetes drug candidate TT-401; and TT-301 and TT-302.

Officers and directors

Tony F. Cruz Ph.D. Chairman of the Board, Chief Executive Officer
Nicole Rusaw Chief Financial Officer
Age: 39
Carl Damiani Chief Operating Officer, Vice President - Business Development
Age: 39
Bruce Connop Vice President - Non-Clinical & Pharmaceutical Development
Age: 43
Aleksandra Pastrak Vice President - Clinical Development and Medical Officer
Age: 46
Louis Alexopoulos Secretary
Michael Richard Dwyer Ashton Lead Independent Director
Age: 68
Paul Baehr Independent Director
Age: 69
Christopher M. Henley Independent Director
Age: 52
Gary W. Pace Ph.D. Independent Director
Age: 66